首页/数据集/Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants

Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants

NCATS Open Data2022-09-16 更新2026-08-08 收录

流感疫苗免疫原性

疫苗加强针效果评估

数据链接：

https://doi.org/10.1101/2022.09.05.22279589 数据链接链接失效反馈

官方服务：

资源简介：

Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants

应用场景：

创建时间：

2022-09-06

多发性硬化症免疫学

流感疫苗免疫原性

IntroductionGiven the varying severity of coronavirus disease 2019 (COVID-19) and the rapid spread of Severe-Acute-Respiratory-Syndrome-Corona-Virus-2 (SARS-CoV-2), vaccine-mediated protection of part

NIAID Data Ecosystem70

Immunogenicity of the reassortant H5N1 virus against homologous and heterologous clade viruses.

流感疫苗免疫原性

病毒分支交叉保护

Immunogenicity of the reassortant H5N1 virus against homologous and heterologous clade viruses.

NIAID Data Ecosystem30

DataSheet_1_Symptomatology during previous SARS-CoV-2 infection and serostatus before vaccination influence the immunogenicity of BNT162b2 COVID-19 mRNA vaccine.pdf

流感疫苗免疫原性

感染后免疫应答

Public health vaccination recommendations for COVID-19 primary series and boosters in previously infected individuals differ worldwide. As infection with SARS-CoV-2 is often asymptomatic, it remains t

NIAID Data Ecosystem10

Hemagglutination-Inhibition Titer

流感疫苗免疫原性

血凝抑制试验抗体滴度

aDose based upon HA contentbInfluenza viruses used in the HAI assay against sera collected at week 5.cHAI GMT plus or minus SEM.dVLP vs. rHA comparing same dose, t-test, *p

Figshare2015-12-02 更新40

Risk of SARS-CoV-2 Omicron (BA.1 lineage) variant infection among people who received booster vaccination relative to booster-eligible people a , according to time after receiving a booster vaccine dose.

疫苗加强针效果评估

Omicron感染风险分析

Risk of SARS-CoV-2 Omicron (BA.1 lineage) variant infection among people who received booster vaccination relative to booster-eligible peoplea, according to time after receiving a booster vaccine dose

NIAID Data Ecosystem20

Safety and immunogenicity of a broad-spectrum mosaic vaccine as a booster dose against SARS-CoV-2 Omicron and other circulating variants

资源简介：

相关数据集